BG
CBPO

Bellevue Group’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bellevue Group’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,500
Closed -$486K – 231
2020
Q1 		$486K Hold
4,500
– – 0.01% 158
2019
Q4 		$524K Hold
4,500
– – 0.01% 165
2019
Q3 		$515K Buy
4,500
+891
+25% +$88.6K 0.01% 155
2019
Q2 		$344K Buy
+3,609
New +$340K 0.01% 172
2017
Q3 		– Sell
-36,250
Closed -$4.1M – 136
2017
Q2 		$4.1M Buy
+36,250
New +$4.05M 0.48% 61

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Bellevue Group's CBPO Position: Q2 2020 in Review

Bellevue Group sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2020, closing a stake of 4,500 shares — an estimated $486K sold.

Bellevue Group first reported a position in CBPO in Q2 2017 and held it in 5 quarters. The position peaked at $4.1M in Q2 2017. 91 funds tracked by Wall St. Rank hold CBPO as of Q2 2020.

  • Bellevue Group reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2020 after selling out during the quarter.
  • Bellevue Group sold 4,500 China Biologic Products Holdings, Inc. shares in Q2 2020, an estimated $486K.
  • Bellevue Group first reported a position in China Biologic Products Holdings, Inc. in Q2 2017 and held it in 5 quarters.
  • Bellevue Group's China Biologic Products Holdings, Inc. position peaked at $4.1M in Q2 2017.
  • 91 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.